Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Curr Treat Options Oncol ; 25(5): 628-643, 2024 05.
Artigo em Inglês | MEDLINE | ID: mdl-38649630

RESUMO

OPINION STATEMENT: Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM. Importantly, the field has learned a great deal from the randomized studies to date. Today, we are continuing to better understand the disease-specific features of the microenvironment in GBM-as well as the exploitable antigenic characteristic of the tumor cells themselves-that are informing the next generation of immune-based therapeutic strategies. The coming phase of next-generation immunotherapies is thus poised to bring us closer to treatments that will improve the lives of patients with GBM.


Assuntos
Neoplasias Encefálicas , Imunoterapia , Microambiente Tumoral , Humanos , Neoplasias Encefálicas/terapia , Neoplasias Encefálicas/imunologia , Imunoterapia/métodos , Microambiente Tumoral/imunologia , Glioblastoma/terapia , Glioblastoma/imunologia , Terapia Combinada/métodos , Resultado do Tratamento , Gerenciamento Clínico , Ensaios Clínicos como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA